Intezyne Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Intezyne Inc (Intezyne) is a biotechnology company that develops product candidates for the treatment of various cancer tumors. The company offers anti-cancer agents and IVECT method to improve cancer therapy. It provides compounds that are cellular or molecularly targeted or have tumor-specific release mechanisms. Intezynes pipeline products include IT-139, IT-141 and IT-147. The companys IT-141 is a formulation of SN-38 encapsulated using its nanoparticle drug delivery platform. It has active preclinical research programs for delivery of DNA and siRNA, molecularly targeted drugs and orally delivered IVECT therapeutics. Intezyne is headquartered in Tampa, Florida, the US.

Intezyne Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
Intezyne Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intezyne Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intezyne Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intezyne Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Intezyne Inc, Medical Devices Deals, 2012 to YTD 2018 9
Intezyne Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Intezyne Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Intezyne Technologies Raises USD10 Million in Series A Preferred Financing 11
Partnerships 12
Exosome Diagnostics Enters into Agreement with Intezyne 12
Acquisition 13
Intezyne Technologies Acquires Niiki Pharma 13
Intezyne Inc - Key Competitors 15
Intezyne Inc - Key Employees 16
Intezyne Inc - Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Mar 15, 2018: Intezyne Taps Veteran Banker E. Russell McAllister as President and CEO 18
Product News 19
04/13/2018: Data Showing that IT-139 Triggers Immunogenic Cell Death (ICD) to Be Presented at AACR 2018 Annual Meeting 19
03/31/2017: Intezyne Technologies Announces Presentation on IT-139 at AACR Symposium 20
03/22/2018: Data on Cancer Resistance Pathway Inhibitor IT-139 to be Presented at AACR 2018 Annual Meeting 21
Product Approvals 22
Jun 20, 2017: Intezyne Technologies Granted Orphan Drug Designation for IT-139 in Pancreatic Cancer 22
Clinical Trials 23
Apr 16, 2018: Intezyne To Showcase Novel Cancer Resistance Pathway Inhibitor IT-139S Potential In Gastric Cancer At ChinaBio Partnering Forum 2018 In Suzhou, PRC 23
Apr 10, 2018: Combination of Checkpoint Inhibitors and Intezynes Novel Cancer Resistance Pathway Inhibitor IT-139 Shows Enhanced Immune Efficacy 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List Of Tables


Intezyne Inc, Pharmaceuticals & Healthcare, Key Facts 2
Intezyne Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intezyne Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intezyne Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intezyne Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Intezyne Inc, Medical Devices Deals, 2012 to YTD 2018 9
Intezyne Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Intezyne Technologies Raises USD10 Million in Series A Preferred Financing 11
Exosome Diagnostics Enters into Agreement with Intezyne 12
Intezyne Technologies Acquires Niiki Pharma 13
Intezyne Inc, Key Competitors 15
Intezyne Inc, Key Employees 16

List Of Figures


Xinjiang Goldwind Science & Technology Co Ltd, Performance Chart (2013 - 2017) 31
Xinjiang Goldwind Science & Technology Co Ltd, Ratio Charts 33
Xinjiang Goldwind Science & Technology Co Ltd, Power, Deals By Year, 2012 to YTD 2018 34
Xinjiang Goldwind Science & Technology Co Ltd, Power, Deals by Type, 2012 to YTD 2018 35

Intezyne Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Intezyne Inc (Intezyne) is a biotechnology company that develops product candidates for the treatment of various cancer tumors. The company offers anti-cancer agents and IVECT method to improve cancer therapy.

USD 250 View Report

Virgin Media Inc - Strategic SWOT Analysis Review

Virgin Media Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information

USD 125 View Report

J.L. Clark Inc - Strategic SWOT Analysis Review

J.L. Clark Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available